Leap Therapeutics Inc. (NASDAQ: LPTX) is 45.00% higher on its value in year-to-date trading and has touched a low of $0.40 and a high of $2.57 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LPTX stock was last observed hovering at around $0.72 in the last trading session, with the day’s loss setting it -0.07% off its average median price target of $3.00 for the next 12 months. It is also 89.17% off the consensus price target high of $6.00 offered by 5 analysts, but current levels are 74.0% higher than the price target low of $2.50 for the same period.
Currently trading at $0.65, the stock is 31.01% and 22.63% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.65 million and changing -9.26% at the moment leaves the stock -35.77% off its SMA200. LPTX registered -72.70% loss for a year compared to 6-month loss of -40.14%.
The stock witnessed a 51.36% gain in the last 1 month and extending the period to 3 months gives it a -25.75%, and is 11.98% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 22.58% over the week and 13.52% over the month.
Leap Therapeutics Inc. (LPTX) has around 36 employees, a market worth around $48.46M and $0.40M in sales. Distance from 52-week low is 63.12% and -74.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-38.40%).
Leap Therapeutics Inc. (LPTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Leap Therapeutics Inc. (LPTX) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 2 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Leap Therapeutics Inc. is expected to release its quarterly report on 05/12/2023.The EPS is expected to grow by 25.40% this year.
Leap Therapeutics Inc. (LPTX) Top Institutional Holders
The shares outstanding are 113.24M, and float is at 82.38M with Short Float at 3.40%.
Leap Therapeutics Inc. (LPTX) Insider Activity
A total of 0 insider transactions have happened at Leap Therapeutics Inc. (LPTX) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Leap Therapeutics Inc. (LPTX): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -56.29% down over the past 12 months.